Cargando…

Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study

BACKGROUND: The purpose of this study was to evaluate the short-term response of intravitreal bevacizumab in diabetic macular edema (DME) and assess the variation in treatment outcomes in different morphology patterns using spectral domain–optical coherence tomography (SD-OCT). OBJECTIVE: To study d...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sadhana, Karki, Pratap, Joshi, Sagun Narayan, Parajuli, Sanket
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977703/
https://www.ncbi.nlm.nih.gov/pubmed/35387237
http://dx.doi.org/10.1177/25158414221074519
_version_ 1784680821333950464
author Sharma, Sadhana
Karki, Pratap
Joshi, Sagun Narayan
Parajuli, Sanket
author_facet Sharma, Sadhana
Karki, Pratap
Joshi, Sagun Narayan
Parajuli, Sanket
author_sort Sharma, Sadhana
collection PubMed
description BACKGROUND: The purpose of this study was to evaluate the short-term response of intravitreal bevacizumab in diabetic macular edema (DME) and assess the variation in treatment outcomes in different morphology patterns using spectral domain–optical coherence tomography (SD-OCT). OBJECTIVE: To study different morphological patterns of DME based on OCT and compare their treatment response to bevacizumab. METHODS: Hundred and twelve eyes of 112 patients with DME were included and treated with intravitreal bevacizumab (1.25 mg/0.05 ml monthly for 3 months). The morphological patterns of DME were classified on the basis of OCT into three groups – diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD) – and changes in central macular thickness (CMT) and best corrected visual acuity (BCVA) after treatment were compared. RESULTS: A total of 112 eyes with DME were included and consisted of 40 DRT, 37 CME, and 35 SRD. Treatment with bevacizumab resulted in decrease in central macular thickness and improvement in BCVA in all three groups. The baseline visual acuity and CMT of DRT group was better than that of the other two groups. The treatment outcome was measured in terms of CMT and BCVA. Change in CMT was statistically significant among three groups and was found to be better in DRT group (p < 0.05, 95% confidence interval). However, there was statistically no significant variation between the three groups regarding the change in BCVA (p = 0.169, 95% confidence interval). CONCLUSION: Anatomic and visual improvement can be achieved by bevacizumab in all patterns of DME. However, individual pattern may respond differently. DRT, which appears to be the earliest form of DME, responds better than other types. Thus, the pattern of macular edema shown by OCT may provide an objective guideline in predicting the response of bevacizumab injection in DME.
format Online
Article
Text
id pubmed-8977703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-89777032022-04-05 Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study Sharma, Sadhana Karki, Pratap Joshi, Sagun Narayan Parajuli, Sanket Ther Adv Ophthalmol Original Research BACKGROUND: The purpose of this study was to evaluate the short-term response of intravitreal bevacizumab in diabetic macular edema (DME) and assess the variation in treatment outcomes in different morphology patterns using spectral domain–optical coherence tomography (SD-OCT). OBJECTIVE: To study different morphological patterns of DME based on OCT and compare their treatment response to bevacizumab. METHODS: Hundred and twelve eyes of 112 patients with DME were included and treated with intravitreal bevacizumab (1.25 mg/0.05 ml monthly for 3 months). The morphological patterns of DME were classified on the basis of OCT into three groups – diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD) – and changes in central macular thickness (CMT) and best corrected visual acuity (BCVA) after treatment were compared. RESULTS: A total of 112 eyes with DME were included and consisted of 40 DRT, 37 CME, and 35 SRD. Treatment with bevacizumab resulted in decrease in central macular thickness and improvement in BCVA in all three groups. The baseline visual acuity and CMT of DRT group was better than that of the other two groups. The treatment outcome was measured in terms of CMT and BCVA. Change in CMT was statistically significant among three groups and was found to be better in DRT group (p < 0.05, 95% confidence interval). However, there was statistically no significant variation between the three groups regarding the change in BCVA (p = 0.169, 95% confidence interval). CONCLUSION: Anatomic and visual improvement can be achieved by bevacizumab in all patterns of DME. However, individual pattern may respond differently. DRT, which appears to be the earliest form of DME, responds better than other types. Thus, the pattern of macular edema shown by OCT may provide an objective guideline in predicting the response of bevacizumab injection in DME. SAGE Publications 2022-03-31 /pmc/articles/PMC8977703/ /pubmed/35387237 http://dx.doi.org/10.1177/25158414221074519 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Sharma, Sadhana
Karki, Pratap
Joshi, Sagun Narayan
Parajuli, Sanket
Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
title Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
title_full Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
title_fullStr Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
title_full_unstemmed Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
title_short Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
title_sort optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab: a short-term study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977703/
https://www.ncbi.nlm.nih.gov/pubmed/35387237
http://dx.doi.org/10.1177/25158414221074519
work_keys_str_mv AT sharmasadhana opticalcoherencetomographypatternsofdiabeticmacularedemaandtreatmentresponsetobevacizumabashorttermstudy
AT karkipratap opticalcoherencetomographypatternsofdiabeticmacularedemaandtreatmentresponsetobevacizumabashorttermstudy
AT joshisagunnarayan opticalcoherencetomographypatternsofdiabeticmacularedemaandtreatmentresponsetobevacizumabashorttermstudy
AT parajulisanket opticalcoherencetomographypatternsofdiabeticmacularedemaandtreatmentresponsetobevacizumabashorttermstudy